



## **Marinomed Biotech AG: Greenshoe option fully exercised**

February 28, 2019

Adhoc-News

Marinomed Biotech AG announces that the greenshoe option from the IPO of 39,000 shares at the offer price of EUR 75 per share was fully exercised. Erste Group Bank AG, acting as stabilising manager, has not conducted any stabilisation activities since the initial listing of the Marinomed shares on 1 February 2019.

After exercising the greenshoe option and subject to the registration of the capital increase in the commercial register planned for next week, the share capital amounts to EUR 1,469,772, split into 1,469,772 voting shares, and the free float amounts to around 39%.

### **About Marinomed Biotech AG**

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at [www.marinomed.com](http://www.marinomed.com).

#### Enquiries:

Eva Prieschl-Grassauer, PhD  
Chief Scientific Officer, Marinomed  
Veterinärplatz 1, 1210 Vienna, Austria  
Tel.: +43 (0)1 250 77 4460  
E-mail: [eva.prieschl@marinomed.com](mailto:eva.prieschl@marinomed.com)  
<http://www.marinomed.com>

Roland Mayrl  
Managing Partner, Metrum Communications  
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria  
Tel.: +43 (0) 1 504 69 87 331  
E-mail: [r.mayrl@metrum.at](mailto:r.mayrl@metrum.at)  
<http://www.metrum.at>

#### Disclaimer

This announcement does not constitute an offer to purchase securities or solicitation of an offer to purchase securities in the United States of America, Germany, Austria or other jurisdictions.

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the

context of such statements or words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project” and “target”. Forward-looking statements speak only as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statement contained in this press release whether as a result of new information, future developments or otherwise.